Medical Devices UK

UK Pharmacogenomic Testing for Psychiatry Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

UK Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $10.7 Mn Placeholder estimate
Estimate 2025 $11.6 Mn 2.4% of the global market
Projected 2034 $23.6 Mn 103.3% Adds $12.0 Mn over 9 forecast years
CAGR 2025–2034 8.2% Faster than 62% of 173 Medical Devices markets here
Key players 5
  • UK is 2.39% of the global market.
  • In Europe, the largest is Germany at $19.4 Mn.
  • Fastest growing: Russia at 10.1% a year.
  • UK ranks 3rd of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$12.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing for Psychiatry Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $10.7 Mn — —
2025 (base) $11.6 Mn +$0.9 Mn —
2026 (forecast) $12.5 Mn +$1.0 Mn +8.2%
2027 (forecast) $13.6 Mn +$1.0 Mn +17.1%
2028 (forecast) $14.7 Mn +$1.1 Mn +26.7%
2029 (forecast) $15.9 Mn +$1.2 Mn +37.1%
2030 (forecast) $17.2 Mn +$1.3 Mn +48.3%
2031 (forecast) $18.6 Mn +$1.4 Mn +60.5%
2032 (forecast) $20.1 Mn +$1.5 Mn +73.6%
2033 (forecast) $21.8 Mn +$1.7 Mn +87.9%
2034 (forecast) $23.6 Mn +$1.8 Mn +103.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UK Pharmacogenomic Testing for Psychiatry Market Analysis at a glance
Market size, 2025$11.6 Mn placeholder estimate
Forecast, 2034$23.6 Mn placeholder estimate
Growth (CAGR), 2025–20348.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all)
Regulator in the UKMHRASource: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UK Pharmacogenomic Testing for Psychiatry Market Analysis Executive Summary

Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.

Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).

Bar chart: UK Pharmacogenomic Testing for Psychiatry market size, 2024–2034, placeholder estimates. $10.7 Mn in 2024, $11.6 Mn in 2025 and $23.6 Mn in 2034, 8.2% CAGR.
UK Pharmacogenomic Testing for Psychiatry market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UK Pharmacogenomic Testing for Psychiatry Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.

Competitive Landscape for Pharmacogenomic Testing for Psychiatry Market in UK

The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing for Psychiatry Market in UK

Pharmacogenomic Testing for Psychiatry in the UK: rules, payment and health figures

Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA).⁠[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.⁠[2] Suicide rate: 10.1 per 100,000 people in 2023, the latest WHO figure for the UK.⁠[3]

[1] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[2] National Institute for Health and Care Excellence. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing for Psychiatry in context

The UK compared

  • Suicide rate: 10.1 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 6 countries we cover in Europe.[2]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 6 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

Free data on this topic

Inside the UK

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing for Psychiatry market in the UK?
Placeholder estimate: about $11.6 Mn in 2025, rising to about $23.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing for Psychiatry market in the UK growing?
Placeholder estimate: about 8.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing for Psychiatry market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Depression, Anxiety, ADHD, Bipolar Disorder) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing for Psychiatry market?
Key players include Myriad Genetics, Inc., Genomind, OneOme, Tempus and Thermo Fisher Scientific Inc..
What is driving the Pharmacogenomic Testing for Psychiatry market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Who regulates Pharmacogenomic Testing for Psychiatry in the UK?
Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA). Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
What does WHO report for the UK?
Suicide rate: 10.1 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the UK are 65 or older?
19.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
How much research is published on Pharmacogenomic Testing for Psychiatry?
PubMed lists 6 papers on Pharmacogenomic Testing for Psychiatry added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in UK

See all

Related on mental health and genomics

See the topic